Τρίτη 3 Ιανουαρίου 2017

Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund

The liver cancer treatment sorafenib should not be available routinely in the NHS in England, but it should continue to be available through the Cancer Drugs Fund, the National Institute for Health...
recent?d=yIl2AUoC8zA recent?d=dnMXMwOfBR0 recent?i=KANIchaEsMw:_xqKdfLo6c0:V_sGLiP recent?d=qj6IDK7rITs recent?i=KANIchaEsMw:_xqKdfLo6c0:gIN9vFw recent?d=l6gmwiTKsz0 recent?d=7Q72WNTAKBA recent?i=KANIchaEsMw:_xqKdfLo6c0:F7zBnMy recent?i=KANIchaEsMw:_xqKdfLo6c0:-BTjWOF


from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iy7edC
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις